StockData
Amylyx Pharmaceuticals, Inc. logo

Amylyx Pharmaceuticals, Inc. (AMLX) stock

AMLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$26.62−0.90 (-3.27%)

Close on Nov 18, 2026Market cap $2.97BP/E –Yield –

Amylyx Pharmaceuticals gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Amylyx Pharmaceuticals's gross profit for the twelve months ending Dec 31, 2025 was $0. For fiscal 2025 it was $0, down 100.0% from the year before.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$0-100.0%
FY2024Dec 31, 2024$81.42M-77.1%
FY2023Dec 31, 2023$355.35M+1747.2%
FY2022Dec 31, 2022$19.24M–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025$0-100.0%
Q3 FY2025Sep 30, 2025$0–
Q2 FY2025Jun 30, 2025$0-100.0%
Q1 FY2025Mar 31, 2025$0-100.0%
Q3 FY2024Sep 30, 2024$416.00K-99.6%
Q2 FY2024Jun 30, 2024-$1.03M-101.1%
Q1 FY2024Mar 31, 2024$82.70M+25.0%
Q4 FY2023Dec 31, 2023$99.09M+419.8%
Q3 FY2023Sep 30, 2023$97.48M+56243.9%
Q2 FY2023Jun 30, 2023$92.64M–
Q1 FY2023Mar 31, 2023$66.15M–
Q4 FY2022Dec 31, 2022$19.06M–
Q3 FY2022Sep 30, 2022$173.00K–

More Amylyx Pharmaceuticals figures

See a number that looks wrong?